modulates cell adhesion 16, 17 and to cell-matrix contacts. 18 PC1 has also been located at the primary cilium of kidney cells, where it is thought to act as a mechanosensitive receptor that transduces mechanical stimuli (fluid flow) into intracellular biochemical signals. [19] [20] [21] PC2 is a smaller transmembrane protein that contains six transmembrane domains, with intracellular C-and N-termini. 3, 22 PC2 belongs to the transient receptor potential family of calcium channels that regulate intracellular calcium and affects various cellular features such as cell proliferation, differentiation and planar cell polarity. [23] [24] [25] Accumulating evidence suggests that both polycystins act as conductors to tune the overall mechanosensitivity of cells. 26 The function of polycystins has mainly been explored in the context of PKD where mutations in the polycystins PC1 and PC2 give rise to a complex cell phenotype, characterized by increased cell proliferation and apoptosis, de-differentiation, disturbed planar cell polarity, extracellular matrix alterations and abnormal fluid secretion. 27 In cancer, however, the function of polycystins is unknown. A comparison between cancer and PKD reveals that both diseases exhibit a deregulation in many important cellular features, such as proliferation, differentiation and apoptosis. 27, 28 Surprisingly, ADPKD cells activate some of the same signalling pathways that are utilized by cancer cells in order to promote their malignant cell behaviour. For example, the mTOR pathway is a critical pathway that is deregulated in both cancer and PKD. mTOR signalling is up-regulated in a wide variety of cancers and is regarded as one of the most frequently altered cascades in this heterogeneous disease. [29] [30] [31] mTOR signalling is increased in mouse models of PKD and human ADPKD, while mTOR inhibitors, such as sirolimus and everolimus, slow disease progression in PKD animal models. 12, [32] [33] [34] The Jak/STAT pathway is also deregulated in both cancer and PKD. Jak/STAT signalling is activated in haematological malignancies, particularly in myeloproliferative neoplasms and solid tumours. [35] [36] [37] In PKD, Jak/STAT signalling activity is abnormally activated and promotes cystic growth. [38] [39] [40] [41] [42] Despite these similarities between cancer and PKD, up to date, there is only one study on the function of polycystins in cancer.
Analysing colorectal cancer (CRC) cell lines (HCT116, HT29 and SW480), HT29 tumour xenografts and cancer tissue samples from CRC patients, Gargalionis et al provided evidence of a role for polycystins in CRC aggressiveness. 43 In the present study, our goal was to examine the in vitro role of PC1 in cancer using cancer cell lines derived from five different types of human cancer (brain-GOS3, lung-A549, prostate-PC3, colon-HT29, breast-MCF7). We found that PC1 modulates the proliferation and migration of cancer cells. We also found that PC1 interacts with mTOR and Jak signalling and affects their activity in cancer cells. Importantly, our study represents the first steps in understanding the function of polycystins in cancer biology.
| MATERIAL S AND ME THODS

| Cell cultures
MCF7, PC3, A549, HT29 and CACO2 cell lines were cultured in DMEM containing L-glutamine, 4.5 g/L D-glucose and pyrophosphate sodium supplemented with 10% foetal bovine serum (FBS) and 1% penicillinstreptomycin (10 000 U/mL penicillin-10 000 mg/mL streptomycin).
GOS3 cancer cells were cultured in RPMI 1640 medium GlutaMAX supplemented with 10% FBS, 1% penicillin-streptomycin (10 000 U/ mL penicillin-10 000 µg/mL streptomycin Fisher Scientific). Cell starvation was performed for 6 hours before transfection in order to achieve proper cell cycle synchronization.
| Antibodies
The following primary antibodies were used for Western blot analysis: 
| Western Blot analysis
Proteins were resolved by electrophoresis in SDS-polyacrylamide gels with varying densities (6% for PC1; 8% for mTOR and p-mTOR; 10% for PC2, Jak2 and p-Jak2; 12% for p70S6K, p-p70S6K, Akt, p-Akt and PTEN;
15% for 4EBP1 and p-4EBP1) and transferred to a nitrocellulose membrane (Porablot NCP, Macherey-Nagel, Duren, Germany). Membranes were incubated overnight at 4°C with the primary antibodies (dilutions were 1:250 for antibodies against PC1, PC2, mTOR, 4EBP1, p70S6K, p-p70S6K; 1:500 for Jak2 and p-Jak2; 1:1000 for p-mTOR, Akt, p-Akt, PTEN, p-4EBP1, actin in PBST containing 1% non-fat milk). Detection of the immunoreactive bands was performed with the LumiSensor Chemiluminescent HRP Substrate kit (GenScript, NJ). Relative protein amounts were evaluated by a densitometric analysis using Image J software and normalized to the corresponding actin levels.
| Cell Proliferation Assay
Cells were seeded in a 96-well plate at a density of 10 was added to each well and mixed gently. The cells were incubated for 4 hours at 37°C in a CO 2 incubator. The absorbance of each sample was measured using a microplate reader at a wavelength of 450 nm.
Cells were synchronized with serum starvation for 6 hours.
| Cell migration assay
HT29, MCF7, PC3, A549 and GOS3 cells were cultured in 12-well cell plates until confluent and synchronized by serum starvation for 6 hours. The cellular layer was etched with a 200 μL sterile pipette tip.
Cells were incubated with IgPKD1 or non-immune rabbit serum. Each location was photographed in a computer-connected microscope (×10 magnification) at zero hour and after 24 hour incubation. Images were analysed using TScratch software. The results were expressed as percentages of the incised and the cell-coated region.
| Statistical and image analysis
All experiments were performed at least three times. Data are presented as mean ± SD and were analysed by one-way ANOVA.
GraphPad Prism 6 software was employed for these statistical analyses. All statistical tests were two-sided. P < 0.05 was considered statistically significant.
| RE SULTS
| Endogenous mRNA and protein expression of PC1 and PC2 in cell lines
PC1 and PC2 proteins have only been detected in SW480 CRC cells, 43 therefore we firstly sought to determine the endogenous mRNA and protein expression levels of the two polycystins in MCF7, PC3, A549, HT29 and GOS3 cancer cell lines. We detected both mRNA (Figure 1A) and protein ( Figure 1B ) levels of PC1 and PC2 in all cell lines apart from PC2 protein in MCF7 cells. There were discrepancies between Pkd1 mRNA levels and PC1 protein levels in some cancer cell lines, as well as discrepancies between Pkd2 mRNA levels and PC2 protein levels.
For example, in MCF7 cells the Pkd2 gene expression is increased but the PC2 protein expression is negligible. These differences may be due to post-transcriptional and post-translational regulatory mechanisms.
In addition, we compared the mRNA and protein levels in the cancer cell lines to the levels in normal cell lines from the same embryonic origin. Our results show that PC1 protein levels were higher in prostate cancer cells (PC3) compared to normal cells (HPrEc) and lower in glioblastoma cells (GOS3) compared to normal brain cells (CHLA-259).
PC2 protein levels were found to be higher in CRC (HT29) and prostate cancer (PC3) cells compared to normal cells (CACO2 and HPrEc respectively), while they were lower in breast cancer cells (MCF7) compared to normal breast cells (MCF10A) ( Figure 1B ). There were no differences observed in the mRNA levels of PC1 and PC2 between cancer and normal cell lines.
| Effect of antibody-mediated PC1 inhibition on cell migration and proliferation in cancer cell lines
Next, we wanted to explore if PC1 affects cancer cell behaviour.
Thus, we decided to investigate whether PC1 affects cell migration and proliferation in cancer cell lines by incubating them with a blocking antibody, IgPKD1, raised against the Ig-like domains of extracellular PC1. 16 Even though the function of PC1 remains obscure, and hence, there is still no specific assay to show that PC1 is inhibited, the IgPKD1 antibody is a valid method of inhibiting PC1. IgPKD1 has been used to block PC1 in murine, canine and human kidney epithelial cells, 16, 17, 44 bone cells, 45, 46 CRC cells and xenografts 43 and endothelial cells. 47 We found that in A549 cells, IgPKD1 treatment led to increased cell migration with the greatest effect observed at a 1:50 dilution of the IgPKD1 antibody ( Figure 2C ). Conversely, in GOS3 cells, blocking PC1 resulted in decreased cell migration with the greatest effect observed at a 1:50 dilution of IgPKD1 ( Figure 2E ).
These results suggest that PC1 function in vitro is cancer cell typespecific, promoting cell migration in GOS3 cells and suppressing cell migration in A549 cells. In terms of cell proliferation, our results
show that MCF7, A549 and HT29 cells exhibited increased cell viability at both 24 and 48 hours after PC1 inhibition ( Figure 3A,3C,3D ).
However, in GOS3 cells, cell proliferation decreased at 48 hours after PC1 inhibition (1:50 dilution of the IgPKD1 antibody) ( Figure 3E ). PC3 cells showed no significant effect on cell proliferation ( Figure 3B ).
These data indicate that PC1 enhances cell proliferation in GOS3 cells but hinders it in MCF7, A549 and HT29 cells.
| Effect of Pkd1 silencing on mTOR pathway in cancer cell lines
Subsequently, we sought to explore the effect of PC1 on mTOR signalling in our cancer cell lines when PC1 protein expression is 
| Effect of antibody-mediated PC1 inhibition on mTOR pathway in cancer cell lines
In a similar fashion to the above experiments, we investigated the effect of PC1 on mTOR signalling in our cancer cell lines, but this We could probably state that mTOR signalling is up-regulated in A549 cells, as there is an increase in both mTOR and p70S6K phosphorylation; however, these two proteins were the only ones to show a significant change in their phosphorylation after PC1 inhibition. Our difficulty in determining mTOR pathway activity after PC1 inhibition may be due to the complexity of its regulation which includes activating or inhibitory inputs from several other pathways. 
| Effect of Pkd1 silencing on Jak pathway in cancer cell lines
To determine the effect of PC1 on the Jak pathway in our cancer cells, we silenced PC1 protein expression through siRNA. The knockdown F I G U R E 3 Effect of PC1 inhibition on cancer cell proliferation. (A-E) Cell proliferation assay in MCF7, PC3, A549, HT29 and GOS3 cells. IgPKD1 is the inhibitory antibody against PC1. Mock represents cells that have been incubated with non-immune rabbit serum (without the IgPKD1 antibody). Each bar represents mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 versus mock at 24 hours. # P < 0.05, ## P < 0.01, ### P < 0.001 versus mock at 48 h 
| Effect of antibody-mediated PC1 inhibition on Jak pathway in cancer cell lines
Finally, we explored the effect of PC1 on the Jak pathway by treating 
| D ISCUSS I ON
Considering the common cellular features and signalling pathways between PKD and cancer, we speculated whether polycystins PC1
and PC2 play a role in cancer biology. First, we sought to evaluate the mRNA and protein levels of polycystins in cell lines from different types of cancer, including glioblastoma, prostate, lung, breast and CRC. We detected both mRNA and protein of PC1 and PC2 in the cancer cell lines. Our results also showed that there were differences in PC1 and PC2 protein levels between cancer cells (PC3, and phosphorylation. In addition, given that PC1 and PC2 physically interact via their cytoplasmic C-terminal tails, it is possible that they modulate each other's subcellular localization, but this remains controversial. 51 Similarly to renal epithelial cells, all cell lines used in our study, apart from glioblastoma cells (GOS3), are epithelial in origin.
However, whether PC1 and PC2 localization in our cancer epithelial cell lines follows the same pattern as in normal renal epithelial cells needs to be investigated in future studies.
For our next experiments, we focused on PC1 because of its large size, flexible nature, participation in cell-cell and cell-matrix contacts and known communication with many downstream signalling pathways via its intracellular C-terminal tail. 7-15 First, we evaluated the effect of PC1 on two important cellular features, cell proliferation and migration, which are commonly deregulated in cancer. 28 Increased cell proliferation is a major feature of a polycystic kidney; cysts have even been characterized as 'neoplasia in disguise'. 52 Several studies have reported that PC1 also regulates cell migration. [53] [54] [55] [56] [57] We found that blocking PC1 in vitro with way. [29] [30] [31] [32] [33] [34] Previous data have demonstrated that PC1 overexpression in SW480 colon cancer cells leads to down-regulation of mTOR signalling. 43 Jak signalling also becomes up-regulated in cancer [35] [36] [37] and studies have shown that PC1 activates Jak signalling in PKD. and HT29 cells. The mTOR suppression observed in HT29 colon cancer cells is consistent with the previous finding that PC1 down-regulates mTOR signalling in SW480 colon cancer cells. 43 These results also suggest that the effect of PC1 on mTOR signalling in cancer is cell type-dependent. Moreover, these data contribute to our knowledge on the regulation of mTOR and Jak signalling in cancer. It should be noted that the conclusions on whether the mTOR cascade is activated or inhibited in cancer cells after changes in PC1 function are based only on the phosphorylation of a single mTOR-related protein.
Likewise, we focused only on Jak2 phosphorylation and did not evaluate any downstream effectors or target genes as surrogate markers of Jak pathway activity. Therefore, our conclusions in terms of Jak signalling activation are solely based on the phosphorylation status of Jak2. The inhibitory or activating effect of PC1 on the two cascades has to be validated through further studies.
A challenge that we encountered in the present study was the following: the two methods used to inhibit PC1 activity, PC1 These discrepancies could be due to limitations inherent in the two methods used to perturb the function of PC1; in contrast to RNAi where the PC1 protein is absent, the IgPKD1-inhibited PC1 protein may lack certain activities but may still execute other activities and/ or interact with other proteins. Moreover, both methods can have substantial off target effects.
In summary, our study demonstrates that PC1 regulates cell proliferation and migration and interacts with mTOR and Jak signalling in various cancer cell lines. Given that there is a lack of prior research on the subject of polycystins and cancer biology, this study represents the first steps towards understanding the function of polycystins in the pathophysiology of cancer. As we expected, our research prompted more question than answers. Future research should focus on the mechanism through which PC1 promotes or inhibits cell proliferation and migration, and the molecular details of the interaction between PC1 and mTOR and Jak signalling. 
ACK N OWLED G EM ENTS
This study was supported by a grant awarded to Kostas A.
Papavassiliou by the Hellenic Society of Medical Oncology (HeSMO).
The IgPKD1 inhibitory antibody was a generous gift from Dr. O.
Ibraghimov-Beskrovnaya and H. Husson (Genzyme Co., Boston, MA).
CO N FLI C T O F I NTE R E S T
The authors declare that there is no conflict of interest.
O RCI D
Kostas A. Papavassiliou https://orcid.org/0000-0001-9620-745X
R E FE R E N C E S
